Bevacizumab in the treatment of HER2-negative breast cancer
Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2008
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727886/ |